DUBLIN, September 12, 2024--ICON shares results of a survey of over 100 oncology drug development professionals on the current state of emerging oncology treatment development.

DUBLIN, May 07, 2025--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma ...

The survey found that investment in AI and digital tools is significant. Over the past five years, the average total investment increase in digital tools is estimated at 34%.

In line with this, 85% of all survey respondents reported having more than one therapeutic approach in development. Additionally, 68% of respondents reported testing at least one combination therapy.